Back to Search

JENNIFER ENG-WONG, MD

MD

Medical Oncology Physician

NPI: 1831234566Individual

Specialties, Licenses & Credentials

Medical Oncology PhysicianPrimary

Internal Medicine — Medical Oncology

Code: 207RX0202X

MD32167(DC)

Research & Publications (13)

Recruitment to a physical activity intervention study in women at increased risk of breast cancer.
PMID 19397816·BMC Med Res Methodol·2009
8-other
Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer.
PMID 18583470·Cancer Epidemiol Biomarkers Prev·2008
3-trial
Current NCI-sponsored Cooperative Group trials of endocrine therapies in breast cancer.
PMID 18072276·Cancer·2008
8-other
Gynecologic and hormonal effects of raloxifene in premenopausal women.
PMID 17662283·Fertil Steril·2007
3-trial
Effect of raloxifene on salivary sex steroid concentrations in premenopausal women.
PMID 17170217·J Endocrinol·2006
3-trial
Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer.
PMID 16868059·J Clin Endocrinol Metab·2006
3-trial
Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer.
PMID 16775175·Cancer Epidemiol Biomarkers Prev·2006
3-trial
Sentinel lymph node biopsy in the management of ductal carcinoma in situ.
PMID 16137431·Clin Breast Cancer·2005
6-review
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
PMID 15709195·Clin Cancer Res·2005
3-trial
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
PMID 15501952·Clin Cancer Res·2004
3-trial
Raloxifene and its role in breast cancer prevention.
PMID 15270657·Expert Rev Anticancer Ther·2004
6-review
Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer.
PMID 14693739·Cancer Epidemiol Biomarkers Prev·2003
3-trial
A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer.
PMID 14531496·Breast Cancer Res Treat·2003
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
3800 RESERVOIR RD NW, LOMBARDI CANCER CENTER
WASHINGTON, DC 20007

Location

Practice Location

3800 RESERVOIR RD NW, WASHINGTON, DC
(202) 444-4948

Quick Facts

NPI
1831234566
Entity Type
Individual
Gender
Female
Medicare
Not confirmed
Specialties
1
Locations
1
Publications
13

Are you this provider?

Claim Your Profile